Clinical Trial Update: Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing paclitaxel with and without PSC 833 in metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• PSC 833 (valspodar)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED